Synaptogenix Q2 2025 Earnings Report

Synaptogenix EPS Results

• Actual EPS: -$11.26
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Synaptogenix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Synaptogenix Announcement Details

• Quarter: Q2 2025
• Date: 8/15/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as part of a corporate rebranding. Its activities have primarily involved research and clinical development in the United States. Synaptogenix has historically traded under the Nasdaq symbol SNPX; the symbol TAOX may not correspond to the company.